04 · Five things to know · 01
Erasca’s pan-RAS pill ERAS-0015 drew confirmed responses in 44% of 25 previously treated pancreatic cancer patients
Must read
What happened
Erasca reported updated Phase 1 data from AURORAS-1 on 11.20 for ERAS-0015, an oral drug it calls a pan-RAS molecular glue that also hits normal, unmutated RAS. At 32 mg once daily, 44% of 25 previously treated pancreatic cancer patients with KRAS G12X mutations had a confirmed response (95% CI about 24 to 65%, our calculation). In the 13 with G12D or G12V, it was 69% (about 39 to 91%). In lung cancer after immunotherapy and platinum it was 60% (n=5), and in biliary tract cancer 75% (n=4). Across 122 patients on 16 to 32 mg, there were no dose-limiting toxicities. At 32 mg, 13.0% had doses interrupted, 16.7% had doses reduced and none stopped. A grade 5 pneumonitis was first disclosed in April 2026. Erasca plans a first-line pancreatic Phase 3 to start in the first half of 2027. Claim
Why it matters
These are small, single-arm groups with no control, so they cannot show the drug beats other treatment, and a response rate is not survival. They add a second pan-RAS drug to a field where daraxonrasib is already approved. Analysis
What we’re watching
Durability of the responses, a full grade 3 or higher adverse event count, and the Phase 3 designs.
Claim CheckPartial
CLAIM CHECK
Partial NCT06983743 registers dose-limiting toxicities, maximum tolerated dose, recommended dose, adverse events and pharmacokinetics as primaries; response rate, the headline, is a secondary.
Also in Five things to know
- Revolution Medicines reported first-line data for daraxonrasib plus chemotherapy in metastatic pancreatic cancer
- Actinogen’s pivotal Xanamem trial in Alzheimer’s disease missed its primary endpoint
- Regeneron’s Livsayis, an RNAi drug discovered by Alnylam, was approved for generalized myasthenia gravis
- AbbVie took an option on AND-gated bispecifics from DISCO; Bloomberg reports Sanofi is weighing a bid for Insmed
Bookmarks need a Mind Club sign-in. How sign-in works
Read it in Five things to know